News & Events

04/07/2022

VI International Congress of the Rheumatic Orthopedics Association

On July 17-18, 2022, Fidia Russia took part in the VI International Congress of the Association of Rheumo-Orthopedists. The event was held in a combined format: face-to-face format with online broadcast. Over 1000 specialists attended the event in 2 days (in person and online) As part of the event,…
21/04/2022

III Congress of Orthobiology 2022 "From research to clinical practice"

On April 15-16, 2022, Fidia Russia took part in the III Congress of Orthobiology 2022 "From research to clinical practice" The event was held in face-to-face format. For 2 days, the event was attended by 400 specialists. Within the framework of the session "Regenerative technologies in…
25/03/2022

VI International School of Association "ARTROMASTER"

On March 18-19, 2022, Fidia Russia took part in the VI International School of the Association "ARTROMASTER", which was held in Kazan. Over 2 days, the event was attended by 250 traumatologists from Russian cities, as well as foreign colleagues. At the Fidia booth, doctors received the latest…
03/11/2021

Scientific and practical conference with international participation "Vredenov readings"

On October 28-29, 2021, Fidia Russia took part in the scientific-practical conference with international participation "Vredenov Readings" The event was held in a combined format: face-to-face with online broadcast Over 2 days, the event was attended by more than 4,000 specialists (in person and…
01/11/2021

Fidia celebrates its 75th anniversary: not a destination, but just one leg of a journey that is going faster than ever

Every day we proudly celebrate the foresight and expertise of those who have helped to build the company, and recognize the vision of those who are already shaping the tomorrow’s world

Founded in 1946, Fidia is celebrating its 75th anniversary with a theme of “Ready for the Future”. This momentous occasion is represented by an image of a tree with solid roots, growing and reaching toward the sky. For us, this anniversary is not a destination, but one leg of a journey that is…
30/10/2021

Distance learning webinar project

Dear partners, Fidia Russia is launching a project of distance learning webinars. This project is aimed at first-table workers. During the webinars, everyone will receive a selection of materials on the company's drugs and will be able to ask questions of interest to specialists. If you want to take…
06/10/2021

V International Congress of the Rheumatic Orthopedics Association

On September 17-18, 2021, Fidia Russia took part in the V International Congress of the Rheumatic Orthopedics Association. The event was held in a combined format: face-to-face format with online broadcast. For 2 days, the event was attended by about 1000 specialists (in person and online). Within…
26/07/2021

Fidia announces the FDA Orphan Drug designation for ONCOFID for the treatment of malignant mesothelioma, the cancer caused by exposure to asbestos

Preclinical studies are underway to complete the pharmaco-toxicological profile, with the aim of submitting the authorisation dossier for human studies to the regulatory authorities by 2022.

Abano Terme (PD), July 26th, 2021 - Fidia Farmaceutici, an Italian company world leader in the research, development, formulation and commercialization of hyaluronic acid-based products, announced today that the U.S. Food and Drug Administration has granted Orphan Drug Designation for ONCOFID-P for…
29/03/2021

V International School of the ARTROMASTER Association

On March 19-20th, the V International School of the ARTROMASTER Association took place in Kazan.More than 200 traumatologists from Russian cities and other countries attended the event, in order to discuss new tendencies of treatment and diagnosis for trauma patients. The products of Fidia Pharma, a…
23/03/2021

Fidia signed a binding agreement with Sanofi for the acquisition of a Sanofi portfolio of anti-inflammatory drugs

The concluded agreement is the result of a selective competitive process launched in 2020, which led Sanofi to choose Fidia among the various participating companies.

Based on this recent operation, the company has strengthened its presence in the prescription drug market, in addition to further expanding its range of products and specialities, thus consolidating its leadership in the Joint Care area and bolstering its business in Dermatology. – Investment in…

Fidia
Farmaceutici S.p.A.
Website

Find out our Corporate Website:

Go to the website

Key Business Areas

Drawing on the strengths of the parent company, Fidia Pharma Russia product portfolio focalizes primarily on joint healthcare.

Fidia Pharma Russia is focused on providing consumers with innovative products that offer quality, safety and performance.